Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis
Abstract Background Immune checkpoint inhibitors (ICIs) can cause serious immune-related
adverse events (irAEs). This study aimed to identify risk factors for all types of irAEs induced …
adverse events (irAEs). This study aimed to identify risk factors for all types of irAEs induced …
Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design
Canakinumab is a human IgGκ monoclonal antibody, with high affinity and specificity for IL-
1β. The Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) trial …
1β. The Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) trial …
[HTML][HTML] First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special …
NE Ready, C Audigier-Valette… - … for immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-
based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in …
based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in …
Corticosteroid administration for cancer-related indications is an unfavorable prognostic factor in solid cancer patients receiving immune checkpoint inhibitor treatment
Y Wang, M Yang, M Tao, P Liu, C Kong, H Li… - International …, 2021 - Elsevier
Objective Immunotherapies targeting immune checkpoints have achieved encouraging
survival benefits in patients with various solid cancers. Corticosteroids are frequently …
survival benefits in patients with various solid cancers. Corticosteroids are frequently …
[HTML][HTML] First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis
F Facchinetti, M Di Maio, F Perrone… - … Lung Cancer Research, 2021 - ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors (ICIs) have become the standard of care for the
first-line treatment of advanced non-small cell lung cancer patients (NSCLC), either as …
first-line treatment of advanced non-small cell lung cancer patients (NSCLC), either as …
Emerging systemic treatment perspectives on brain metastases: moving toward a better outlook for patients
C Alvarez-Breckenridge, J Remon, Y Piña… - American Society of …, 2022 - ascopubs.org
The diagnosis of brain metastases has historically been a dreaded, end-stage complication
of systemic disease. Additionally, with the increasing effectiveness of systemic therapies that …
of systemic disease. Additionally, with the increasing effectiveness of systemic therapies that …
Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression
K Wakuda, M Yabe, H Kodama, N Nishioka… - Lung Cancer, 2021 - Elsevier
Objectives Pembrolizumab is recommended for patients with previously untreated non-small
cell lung cancer (NSCLC) with a programmed death ligand 1 (PD-L1) tumor proportion score …
cell lung cancer (NSCLC) with a programmed death ligand 1 (PD-L1) tumor proportion score …
Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
J Sheng, H Li, X Yu, S Yu, K Chen, G Pan… - Thoracic …, 2021 - Wiley Online Library
Background There is only limited knowledge of the treatment responses and clinical
outcomes of immune checkpoint inhibitors (ICIs) in driver gene‐negative non‐small cell lung …
outcomes of immune checkpoint inhibitors (ICIs) in driver gene‐negative non‐small cell lung …
Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data
T Macioch, M Krzakowski, K Gołębiewska, M Dobek… - Discover Oncology, 2024 - Springer
The efficacy of pembrolizumab in the treatment-naïve non-small-cell lung cancer (NSCLC)
patients was proved in the KEYNOTE-024 randomized trial. The aim of this systematic …
patients was proved in the KEYNOTE-024 randomized trial. The aim of this systematic …
Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic …
B Yang, B Wang, Y Chen, N Wan, F Xie, N Yang… - Frontiers in …, 2023 - frontiersin.org
Background Several randomized controlled trials (RCTs) have confirmed the favorable
clinical benefit of pembrolizumab in advanced non-small cell lung cancer (NSCLC) …
clinical benefit of pembrolizumab in advanced non-small cell lung cancer (NSCLC) …